- Details
- (Length of Discussion: 20 min) Prostate cancer in African-American men remains a major public health issue. Judd W Moul, MD, reviews the history of the U.S. Preventive Services Task Force screening guidelines and highlights the US trends and patterns of disparities in cancer mortality among U.S. counties from 1980 to 2014. He touches on the molecular differences that may explain, in part, the aggr...
|
- Details
- (Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...
|
- Details
- (Length of Discussion: 15 min) Tom Keane and See-Tong Pang discuss the results of a prospective clinical study utilizing a novel circulating tumor cells (CTC) blood assay to clarify PSA results in 200 men who present with a PSA of 4ng/ml-10ng/ml. The CellMax CTC Platform is used to isolate CTCs to assess NPV and PPV for Gray Zone patients. Isolated CTCs may also be analyzed for the presence of pro...
|
- Details
- (Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...
|
- Details
- (Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...
|
- Details
- (Length of Conversation: 7 min) Sigrid Carlsson, MD talks with Alicia Morgans, MD about long-term outcomes of active surveillance for prostate cancer, a 17-year experience with active surveillance at the Memorial Sloan Kettering Cancer Center. A study which Carlsson was a co-author on and was presented at the most recent American Urological Association meeting (AUA2018). This was a retrospective a...
|
- Details
- (Length of Conversation: 10 min) Felix Feng, MD talks with Alicia Morgans, MD, MPH on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up...
|
- Details
- (Length of Presentation: 16 min) Alicia Morgans, MD presents a Geriatric Assessment of Men with Prostate Cancer. She outlines the importance of geriatric considerations in prostate cancer and implementing it into the clinical management of patients. She details initial treatment decision making including staging the aging and estimation of remaining life expectancy. She also discusses consideratio...
|
- Details
- (Length of Discussion: 18 min) Dr. Robert Hamilton, a Staff Urologic Oncologist from Princess Margaret Cancer Centre in Toronto, Canada discusses radical prostatectomy for patients with oligometastatic prostate cancer. He overviews the clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging. He reviews four major PET trace...
|
- Details
- (Length of Discussion: 15 min) Dr. Lawrence I. Karsh discusses SpaceOAR Hydrogel and it's use as a prostate-rectum spacer for treating prostate cancer with radiation therapy. He presents a study he took part in which aimed to evaluate the safety of the prostate-rectum spacer application technique as well as the following: the implant quality and resulting rectal dose reduction, acute and long term...
|
